Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Tonix Pharmaceuticals Holding / Equity Bottom-Up

<ul><li>On May 12, 2025, Tonix Pharmaceuticals Holding Corp. (TNXP) announced financial results for the first quarter of 2025 and provided a business update.</li><li>The company is continuing pre-commercialization activities in preparation for the PDUFA date of August 15, 2025 for TNX-102 SL for the management of fibromyalgia.</li><li>If approved, TNX-102 SL would be the first new treatment option for fibromyalgia in more than 15 years.</li></ul>

On May 12, 2025, Tonix Pharmaceuticals Holding Corp. (TNXP) announced financial results for the first quarter of 2025 and provided a business update.The company is continuing pre-commercialization activities in preparation for the PDUFA date of August 15, 2025 for TNX-102 SL for the management of fibromyalgia.If approved, TNX-102 SL would be the first new treatment option for fibromyalgia in more than 15 years.

TNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia 